The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Type I IFN Protects Against Murine Lupus
Open accessAbstract
Both the type I (IFN-αβ) and type II (IFN-γ) IFNs have been heavily implicated in the pathogenesis of systemic lupus erythematosus. To test the relative roles of these systems, congenic lupus-prone MRL/CD95lpr/lpr (MRL/lpr) mice lacking the type I IFN receptor (IFN-RI), type II IFN receptor (IFN-RII), or both, were derived. As expected, deficiency for IFN-RII protected MRL/lpr mice from the development of significant autoimmune-associated lymphadenopathy, autoantibodies, and renal disease. However, deficiency for the IFN-RI surprisingly worsened lymphoproliferation, autoantibody production, and end organ disease; animals doubly deficient for IFN-RI and IFN-RII developed an autoimmune phenotype intermediate between wild-type and IFN-RII-deficient animals, all correlating with an ability of type I IFN to suppress MRL B cell activation. Thus, type I IFNs protect against both the humoral and end organ autoimmune syndrome of MRL/lpr mice, independent of IFN-γ. These findings warrant caution in the use of type I IFN antagonists in the treatment of autoimmune diseases and suggest further investigation into the interplay between the types I and II IFNs during the ontogeny of pathogenic autoantibodies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CELLULAR RESPONSES TO INTERFERON-γ
Boehm, U., Klamp, T., Groot, M., & Howard, J. C. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.749 · Cited by 2,890
T-bet is rapidly induced by interferon-γ in lymphoid and myeloid cells
Lighvani, A. A., Frucht, D. M., Jankovic, D., Yamane, H., Aliberti, J., Hissong, B. D., Nguyen, B. V., Gadina, M., Sher, A., Paul, W. E., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.261570598 · Cited by 783 · cited 1×
“Indeed, the only definitively demonstrated pathogenic target of the IFNs in humoral autoimmunity, the T-box transcription factor T-bet, is an IFN, but not type I IFN-, induced gene (11, 26), suggesting that perhaps the role of the type I IFNs is adjunctive to IFN.”
Background
Cited by
TYPE I INTERFERONS (α/β) IN IMMUNITY AND AUTOIMMUNITY
Theofilopoulos, A. N., Baccala, R., Beutler, B., & Kono, D. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115843 · Cited by 1,185
Type I Interferon in Systemic Lupus Erythematosus and Other Autoimmune Diseases
Banchereau, J., & Pascual, V. (2006) · Immunity · doi:10.1016/j.immuni.2006.08.010 · Cited by 963
Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus
Christensen, S. R., Kashgarian, M., Alexopoulou, L., Flavell, R. A., Akira, S., & Shlomchik, M. J. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050338 · Cited by 516
TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity
Baccala, R., Hoebe, K., Kono, D. H., Beutler, B., & Theofilopoulos, A. N. (2007) · Nature Medicine · doi:10.1038/nm1590 · Cited by 473
Knight, J. S., Subramanian, V., O'Dell, A. A., Yalavarthi, S., Zhao, W., Smith, C. K., Hodgin, J. B., Thompson, P. R., & Kaplan, M. J. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-205365 · Cited by 443
Peptidylarginine deiminase inhibition is immunomodulatory and vasculoprotective in murine lupus
Knight, J. S., Zhao, W., Luo, W., Subramanian, V., O’Dell, A. A., Yalavarthi, S., Hodgin, J. B., Eitzman, D. T., Thompson, P. R., & Kaplan, M. J. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67390 · Cited by 389
Osteopontin expression is essential for interferon-α production by plasmacytoid dendritic cells
Shinohara, M. L., Lu, L., Bu, J., Werneck, M. B. F., Kobayashi, K. S., Glimcher, L. H., & Cantor, H. (2006) · Nature Immunology · doi:10.1038/ni1327 · Cited by 360
The pathogenesis of systemic lupus erythematosus—an update
Choi, J., Kim, S. T., & Craft, J. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.10.004 · Cited by 360
The type I interferon system in systemic lupus erythematosus
Rönnblom, L., Eloranta, M., & Alm, G. V. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21571 · Cited by 341
Systemic lupus erythematosus: all roads lead to type I interferons
Pascual, V., Farkas, L., & Banchereau, J. (2006) · Current Opinion in Immunology · doi:10.1016/j.coi.2006.09.014 · Cited by 285
Savarese, E., Chae, O.-W., Trowitzsch, S., Weber, G., Kastner, B., Akira, S., Wagner, H., Schmid, R. M., Bauer, S., & Krug, A. (2006) · Blood · doi:10.1182/blood-2005-07-2650 · Cited by 271
Mathian, A., Weinberg, A., Gallegos, M., Banchereau, J., & Koutouzov, S. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.5.2499 · Cited by 270
B cells as therapeutic targets in SLE
Sanz, I., & Lee, F. E.-H. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.68 · Cited by 261
Regulation of autoreactive B cell responses to endogenous TLR ligands
Avalos, A. M., Busconi, L., & Marshak-Rothstein, A. (2010) · Autoimmunity · doi:10.3109/08916930903374618 · Cited by 114
“lprmice display more severe disease than IFNAR þ littermates [63].”
BackgroundType I interferons and endoplasmic reticulum stress in health and disease
(2020) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2019.10.004 · Cited by 83
Metadata
- Authors
- Hron, J. D., & Peng, S. L.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-08-01
- Volume
- 173
- Issue
- 3
- Pages
- 2134-2142
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1924968745
- Cited by
- 201
- References
- 2
- FWCI
- 9.56
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.